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Abstract
Two amino acids (lysine at position 627 or asparagine at position 701) in the polymerase subunit PB2 protein are considered
critical for the adaptation of avian influenza A viruses to mammals. However, the recently emerged pandemic H1N1 viruses
lack these amino acids. Here, we report that a basic amino acid at position 591 of PB2 can compensate for the lack of lysine
at position 627 and confers efficient viral replication to pandemic H1N1 viruses in mammals. Moreover, a basic amino acid at
position 591 of PB2 substantially increased the lethality of an avian H5N1 virus in mice. We also present the X-ray
crystallographic structure of the C-terminus of a pandemic H1N1 virus PB2 protein. Arginine at position 591 fills the cleft
found in H5N1 PB2 proteins in this area, resulting in differences in surface shape and charge for H1N1 PB2 proteins. These
differences may affect the protein’s interaction with viral and/or cellular factors, and hence its ability to support virus
replication in mammals.
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Introduction
Influenza viruses pose an ongoing threat to human health, as
underscored by the current H1N1 influenza pandemic and the
sporadic transmission of highly pathogenic avian H5N1 influenza
viruses to humans [1,2]. Viral determinants of virulence and
transmissibility are still poorly understood, although lysine at
position 627 of the polymerase subunit PB2 (PB2-627K) is now
known to be important for avian influenza virus adaptation to
mammals [3,4]. Most avian influenza viruses (with the exception
of the Qinghai Lake-lineage of H5N1 viruses) possess glutamic
acid at this position (PB2-627E), whereas most human influenza
viruses (with the notable exception of the current pandemic H1N1
viruses) have lysine (PB2-627K). In addition, replacement of the
aspartic acid at position 701 of PB2 (PB2-701D) found in most
avian influenza viruses with asparagine (PB2-701N) conferred high
pathogenicity to an H5N1 influenza virus in mice [5]. These
mammalian-type amino acids (i.e., PB2-627K and PB2-701N) are
found in some H5N1 (http://www.flu.lanl.gov) or H7N7 [6]
influenza viruses isolated from humans, are selected during
replication of H5N1 viruses in humans [7], and facilitate virus
transmission in ferret [8] and guinea pig models [9]. Collectively,
these results have led to the concept that PB2-627K or PB2-701N
are critical for efficient influenza virus replication in mammalian
species. Nevertheless, the pandemic H1N1 viruses and some
H5N1 influenza viruses isolated from humans do not possess these
PLoS Pathogens | www.plospathogens.org 1 August 2010 | Volume 6 | Issue 8 | e1001034amino acids. Here, we sought to identify additional amino acid
changes that facilitate virus adaptation in mammalian species.
Results/Discussion
Lysine at position 591 of the PB2 protein confers efficient
replication to an H5N1 influenza virus in mammals
An H5N1 influenza virus isolated from an infected person in
Indonesia in 2005 (A/Indonesia/UT3006/05, UT3006) replicated
more efficiently than an avian H5N1 virus (A/chicken/Indonesia/
UT3091/05 virus; CkUT3091) in normal human bronchioepithe-
lial (NHBE) cells (Fig. 1), despite having avian-type amino acids at
PB2-627 and PB2-701. In addition, the mouse lethal dose 50
(MLD50) of UT3006 is 180 plaque-forming units (PFU), indicating
appreciable virulence in mice. Reverse genetics approaches
demonstrated a critical role of the UT3006 PB2 segment in
facilitating more efficient growth of UT3006-CkUT3091 reassor-
tants in NHBE cells (Fig. 1A). Although the UT3006 and
CkUT3091 PB2 proteins both encode the avian-type amino acids
at positions 627 and 701, they differ by nine other amino acids (62-
R/K, 117-T/I, 288-R/Q, 344-M/V, 524-T/I, 526-K/R, 591-Q/
K, 676-K/T, 756-T/M; where the first amino acid indicates the
residue found in CkUT3091 and the second indicates that found
in UT3006). Five of these changes (at positions 62, 117, 524, 526,
and 591) are not commonly found in avian influenza viruses,
suggesting that they may play a role in mammalian adaptation.
Introduction of the UT3006 sequence at these five sites
appreciably increased the replicative ability of CkUT3091 in
NHBE cells (CkUT3091-5aa, Fig. 1B), although virus titers did not
reach the level of UT3006 virus. The respective changes were
tested individually for their ability to facilitate avian influenza virus
replication in human cells and introduction of the PB2-Q591K
change appreciably enhanced the growth properties of CkUT3091
in NHBE cells (Fig. 1B). In contrast, the CkUT3091 variant
possessing the PB2-T117I mutant was comparable in its growth to
the parental CkUT3091 virus (Fig. 1B). The mutants containing
PB2-R62K, PB2-T524I, or PB2-K526R changes were not viable,
suggesting that these residues require compensatory changes at
other sites. These findings suggest that, in the absence of PB2-
627K or 701N, PB2-591K is a key amino acid for efficient
influenza virus replication in human cells. Hence, replacement of
the highly conserved glutamine at position 591 with lysine may
facilitate mammalian adaptation in the context of an avian-type
PB2 protein.
Next, we tested CkUT3091 and its mutant possessing the PB2-
Q591K substitution (CkUT3091-PB2-Q591K) for their virulence
in mice. All mice infected intranasally with high doses of virus [10
6
or 10
5 PFU of virus] lost more than 25% of their pre-infection
weight and had to be euthanized on day 4 or 5 post-infection
(Fig. 2A and B). At lower infection doses (10
2–10
4 PFU), most
animals infected with CkUT3091 virus survived (Figs. 2C–E),
while all mice infected with CkUT3091-PB2-Q591K had to be
euthanized. At the lowest doses tested (10
1 PFU), infected animals
did not experience significant weight loss and survived (Fig. 2F).
The MLD50 was 10
4.3 PFU for CkUT3091 and 50 PFU for the
mutant possessing PB2-Q591K (CkUT3091-PB2-Q591K). These
findings demonstrated that the glutamine-to-lysine mutation at
position 591 of PB2 increased the virulence of an avian H5N1
influenza virus in mice.
Lysine at position 591 of the PB2 protein is selected
during H5N1 virus replication in ostrich cells
We previously reported that the human-adapting amino acids
PB2-627K and PB2-701N are not only selected during replication
of avian influenza viruses in mammalian cells, but also during
replication of avian H5N1 viruses in cultured primary ostrich cells
or ostriches [10]. Although not fully understood, the selection
processes in ostriches thus appear to mimic those in mammalian
cells. Since the significance of PB2-591 had not been recognized at
the time, we focused our previous analysis on PB2-627 and PB2-
701. Here, we therefore reexamined all amino acid changes
acquired during replication of A/duck/Vietnam/5001/04 (H5N1)
or A/duck/Vietnam/NCVD-18/03 (H5N1) in ostrich cells in vitro
or in vivo. PB2-591K was not detected after replication of A/duck/
Vietnam/NCVD-18/03 in an infected ostrich, but 12 of 73 PB2
molecular clones derived from viruses isolated from the trachea of
an ostrich infected with A/duck/Vietnam/5001/04 (originally
possessing PB2-591Q) had acquired the PB2-591K substitution
(Table 1). Interestingly, five passages of A/duck/Vietnam/5001/
04 in ostrich embryonic cells also yielded one clone (out of 16) with
a PB2-Q591R mutation, as found in pandemic H1N1 viruses (see
below). Comparable to mammalian cells, the replication of avian
H5N1 influenza viruses in ostriches thus resulted in the selection of
a basic amino acid at position 591; it is interesting to note that
both PB2-591K (as found in some mammalian-adapted H5N1
viruses) and PB2-591R (as found in pandemic H1N1 viruses) were
detected. The observed differences in adaptation to ostriches
between the two duck viruses may result from differences in their
genetic composition. The selection of a basic amino acid at PB2-
591 in ostrich cells that seem to mimic the selective pressure in
mammals provided further support for the role of PB2-591 in
avian influenza virus adaptation to mammalian species.
All 12 ostrich PB2 clones possessing the PB2-591K mutation
encoded PB2-627E (i.e., the wild-type, avian-type amino acid;
Table 1). Conversely, the remaining 61 clones acquired the PB2-
627K (mammalian-type) mutation but encoded the wild-type
amino acid at position 591 (PB2-591Q) (Table 1). These findings
from our in vivo selection study are consistent with three published
ostrich sequences (Supplementary Figure S1) that show the PB2-
591Q/627K or PB2-591K/627E combinations, but not mutations
at both positions (i.e., PB2-591K/627K). Hence, PB2-591K
appears to be selected in combination with PB2-627E, but not
in combination with PB2-627K, suggesting that PB2-591K may
functionally compensate for the lack of a positive charge at
position 627.
Author Summary
Influenza viruses that originate from avian species likely
have to acquire adapting amino acid changes to replicate
efficiently in mammals. Two amino acid changes in the
polymerase PB2 protein—a glutamic acid to lysine change
at position 627 or an aspartic acid to asparagine change at
position 701—are known to allow influenza viruses of
avian origin to replicate efficiently in mammals. Interest-
ingly, the pandemic H1N1 viruses (which possess an avian-
like PB2 gene) do not encode the ‘human-type’ amino
acids PB2-627K and PB2-701N. Here, we report that a basic
amino acid at position 591 of PB2 can compensate for the
lack of PB2-627K and allows efficient replication of highly
pathogenic H5N1 and pandemic H1N1 viruses in mam-
malian species. We also present the X-ray crystal structure
of the C-terminal portion of a pandemic H1N1 PB2 protein.
The basic amino acid at position 591 fills a distinctive cleft
found in the PB2 proteins of H5N1 viruses. We also
speculate on the biological significance of the altered
surface of the H1N1 PB2 protein.
A Host-Adapting Amino Acid in Influenza Virus
PLoS Pathogens | www.plospathogens.org 2 August 2010 | Volume 6 | Issue 8 | e1001034Figure 1. Amino acid PB2-591 is important for H5N1 virus replication in mammalian cells. A. We inoculated the human UT3006 virus, the
avian CkUT3091 virus, or CkUT3091-based reassortant viruses possessing single genes of UT3006 (CkUT3091-UT3006PB2, -UT3006PB1, -UT3006PA, -
UT3006HA, -UT3006NP, -UT3006NA, -UT3006M, and -UT3006NS) into normal human bronchioepithelial (NHBE) cells at a multiplicity of infection of
0.0005 and cultured infected cells at 37uC. The culture supernatants were harvested at the indicated times and subjected to plaque assays in NHBE
cells to determine virus titers. B. Growth curves in NHBE cells of UT3006, CkUT3091, and CkUT3091 variants possessing UT3006-derived PB2
substitutions at position 117 (PB2-T117I), 591 (PB2-Q591K), or at all five positions indicated in the text (PB2-5aa). The CkUT3091 virus possessing the
UT3006-PB2 gene (CkUT3091-UT3006PB2, see Fig. 1A) is shown again for comparison. Experiments to determine viral growth kinetics were carried
out twice, with three explicates each. Shown are data from one experiment.
doi:10.1371/journal.ppat.1001034.g001
A Host-Adapting Amino Acid in Influenza Virus
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H1N1 viruses
Our data indicated that a basic amino acid at PB2-591 can
compensate for PB2-627K in mammalian adaptation; interesting-
ly, these two residues are positioned near each other on the surface
of PB2 [11,12]. These findings offered an explanation for the
efficient replication of the newly emerged pandemic H1N1 viruses
in humans: although these viruses lack mammalian-type amino
acids at position 627 and 701, they encode a basic amino acid (i.e.,
arginine) at position 591 (PB2-591R). In fact, a recent study
demonstrated that PB2-590S and PB2-591R are important for
efficient polymerase activity in an in vitro assay, and for efficient
replication of a mixed human/avian influenza virus (with the
polymerase and nucleoproteins of avian virus origin) in human
cells [13]. Importantly, the additional introduction of PB2-627K
did not increase the replicative ability of the mutant virus further
[13], consistent with our finding that the combination of basic
amino acids at positions 591 and 627 is not selected for in vivo.
However, these studies were not carried out with authentic
pandemic H1N1 virus and therefore leave in question the
biological significance of PB2-591R for the efficient replication
of pandemic H1N1 viruses in humans.
To test the significance of specific PB2 amino acid changes in
the background of authentic pandemic H1N1 viruses in animal
models, we first generated the following PB2 protein variants that
were all based on A/California/04/09 (Cal04), an early pandemic
H1N1 virus that we previously characterized in vitro and in several
animal models [14]: (i) wild-type PB2, (ii) PB2-627K (mammalian-
Figure 2. Amino acid PB2-591K increases the virulence of an avian H5N1 virus in mice. Mice (4 per group) were inoculated with the
indicated amounts of CkUT3091 virus (blue squares) or CkUT3091 virus possessing the PB2-Q591K substitution (red circles) and observed daily for
changes in body weight. Animals that lost more than 25% of their pre-infection weight were euthanized. The numbers in the graphs indicate the
numbers of surviving mice per group. A.–F. Infection of mice with 10
6 pfu (A), 10
5 pfu (B), 10
4 pfu (C), 10
3 pfu (D), 10
2 pfu (E), or 10
1 pfu (F) of virus.
doi:10.1371/journal.ppat.1001034.g002
A Host-Adapting Amino Acid in Influenza Virus
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lian-type) instead of PB2-701D (avian-type), or (iv) PB2-591Q
(consensus amino acid at this position) instead of PB2-591R (found
in pandemic H1N1 viruses). These variants were assessed for their
polymerase activity in minireplicon assays, essentially as described
[15]. Replacement of PB2-591R with PB2-591Q reduced the
polymerase activity (Supplementary Figure S2), further indicating
a critical role of PB2-591R in efficient pandemic H1N1 virus
replication. Replacement of PB2-627E with PB2-627K, or of PB2-
701D with PB2-701N, had mild or no effects. Herfst et al. [16]
recently reported increased polymerase activity in minireplicon
assays for pandemic H1N1 variants possessing the PB2-627K or
PB2-701N mutations, but used different pandemic H1N1 virus
isolates.
Next, the PB2 mutations described above were introduced into
the genetic background of Cal04 virus, using reverse genetics.
Growth curves in Madin-Darby canine kidney (MDCK) cells
revealed no significant differences (Supplementary Figure S3), as
has been reported by others for the PB2-627K and PB2-701N
variants [16,17]. Intranasal inoculation of BALB/c mice with 10
4
or 10
5 PFU of virus resulted in increased weight loss for the PB2-
627K and PB2-701N variants (Supplementary Figure S4);
however, virus titers in the lungs and nasal turbinates on days 3
and 6 post-infection were comparable for all variants tested
(Supplementary Table S1). Similar findings (i.e., weight loss in
mice, but no increase in virus titers) were recently reported by
others for pandemic H1N1 viruses possessing PB2-627K or PB2-
701N [16,17]. The effects of mutations in PB2 on pandemic H1N1
viruses were further tested in competitive transmission studies in
ferrets, an established animal model in influenza virus research; in
addition, pandemic H1N1 viruses are known to efficiently transmit
in ferrets [14,18,19]. Wild-type Cal04 (PB2-591R/627E/701D)
and its PB2 variants (PB2-591R/627K/701D, PB2-591R/627E/
701N, or PB2-591Q/627E/701D) were mixed at a 1:1 ratio based
on plaque-forming units; however, deep sequencing revealed a
slight excess of wild-type Cal04 PB2 vRNA over mutant PB2
vRNAs (Fig. 3B–D). Three ferrets (one per cage) were infected
intranasally with virus mix. One day later, one ferret each was
placed in a cage adjacent to an infected ferret (‘contact’ ferret) to
monitor virus transmission by aerosols. At the indicated time
points, nasal wash samples were assessed for the relative ratios of
the two viruses (Figs. 3B–D; and Supplementary Table S2). In
both infected and contact ferrets, mutations at position PB2-627
(PB2-591R/627K/701D) or PB2-701 (PB2-591R/627E/701N)
did not provide a replicative advantage to the respective viruses
when compared to wild-type Cal04 virus (PB2-591R/627E/
701D). This is consistent with recent findings that E627K or
D701N mutations did not affect the virulence or transmissibility of
pandemic H1N1 viruses in ferrets [16]. However, in competition
studies between wild-type Cal04 virus and a mutant virus
possessing PB2-591Q (PB2-591Q/627E/701D), the relative
amounts of Cal04 virus increased over time in infected animals
(Fig. 3D), indicating that in the background of PB2-627E/701D,
PB2-591R provides a replicative advantage over PB2-591Q (the
amino acid commonly found at this position). Interestingly, two
out of three contact animals showed enrichment of the PB2-591Q
mutant virus on day 3 after co-housing; thus, although further
studies with larger numbers of animals are needed, we speculate
that PB2-591Q might enhance transmission, but not replication in
the new host. Collectively, our findings supported the hypothesis
that PB2 possessing 591R supports efficient viral replication in
mammals, so that there is no strong selective pressure to acquire
the mammalian-type amino acids at position 627 and 701.
Based on our experimental data and the evaluation of published
influenza virus sequences, we suggest the following scenario:
efficient replication in mammalian species can be conferred by
PB2-591Q/627K [found in some avian H5N1 viruses that
acquired the ability to replicate in mammalian cells [7] (http://
www.flu.lanl.gov), and found in human influenza viruses], PB2-
591K/627E [found in some avian H5N1 viruses that acquired the
ability to replicate in mammalian cells, (http://www.flu.lanl.gov),
and identified in this study], or PB2-591R/627E (found in
pandemic H1N1 viruses). However, the combination of PB2-
591R/K and PB2-627K does not seem to further enhance
replication in mammalian cells (Figs. 3B and C). Currently, it is
not clear why PB2-591R is found in pandemic H1N1 viruses,
while PB2-591K is selected in avian H5N1 viruses. In addition,
PB2-701N also confers to H5N1 viruses the ability to replicate in
mammalian cells in the absence of PB2-627E [5]. Moreover, other
amino acids changes in PB2 may confer efficient replication in
mammalian species as well (for example, [20,21]).
Crystal structure of the C-terminal portion of PB2 from a
2009 H1N1 pandemic virus
Previous X-ray crystallographic studies have demonstrated the
close proximity of residues 591 and 627on the surface ofPB2[11,12].
This has lead to the suggestion (based on modeling) that PB2-591R
neutralizes the PB2-627E in pandemic H1N1 viruses, and thereby
partially restores the positively charged surface of the 627 domain of
PB2 [13]. To address this critical question, we present here the high-
resolution crystal structure of the C-terminal domain of PB2 from
a 2009 H1N1 pandemic virus (A/Mexico/InDRE4487/2009)
(Fig. 4A); the PB2 proteins of A/Mexico/InDRE4487/2009 and
Cal04 are identical in the region crystallized; i.e., amino acid residues
538–741. For comparison, we also present the crystal structure of the
C-terminal portion of an H5N1 PB2 protein encoding PB2-627K (A/
Vietnam/1203/04; Fig. 4B).
The PB2 protein of the pandemic H1N1 virus shows an altered
polar surface when compared to the avian H5N1 PB2-627K
protein. Interestingly, our structure of the pandemic H1N1 PB2
protein reveals that PB2-591R fills the cleft found in H5N1 PB2
proteins in this area (compare Fig. 4A and 4B). In particular, the
side chains of R591 and S590 in the structure of H1N1 PB2
occupy what would otherwise be the positively charged cleft in the
H5N1 PB2. PB2-591R is located 4 A ˚ngstrom from PB2-627E,
Table 1. Mammalian-type amino acids in the PB2 protein of
ostrich isolates.
Virusa No. of clones PB2 amino acid
b at position:
591 627 701
Inoculum 50/50 Q E D
Brain isolate 35/35 Q K D
Trachea isolate 61/73 Q K D
12/73 K ED
Lung isolate 33/57 Q E D
24/57 Q K D
aWe intratracheally inoculated A/duck/Vietnam/5001/04 (H5N1) into a 3-week-
old ostrich and isolated virus from trachea, lungs, and brain on day 3 post-
infection (for more details, see [10]). Viral RNA was isolated, and the PB2 gene
was amplified by RT-PCR and cloned. We then sequenced the indicated
numbers of PB2 clones. Results for PB2-627 and PB2-701 were already shown
in Shinya et al. [10]. We here expanded our analysis to include PB2-591 in this
study.
bMammalian-type amino acids are shown in bold and italics.
doi:10.1371/journal.ppat.1001034.t001
A Host-Adapting Amino Acid in Influenza Virus
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participating in hydrogen-bonded and water-mediated hydrogen
bond networks with the main chain carbonyl backbone between
residues A587 and T588 (Fig. 4C), even though the two residues
have space to assume rotomers that could form a neutralizing salt
bridge (see Fig. 4C). The R591 residue in H1N1 PB2 thus affects
both the shape and charges on the surface of the protein, which
may affect its interaction with other viral and/or host factors.
A previous study [22] suggested that an inhibitory host factor
may suppress the activity of avian-type polymerases (possessing
PB2-627E), but not that of human-type polymerases (possessing
PB2-627K). In this scenario, the positively charged residue (PB2-
591R) that rotates away from PB2-627E may prevent the
inhibitory host factor from interacting with PB2 by either charged
repulsion or steric hindrance by filling the distinct cleft on the
surface of the H5N1 PB2. Alternatively, the positive charge
Figure 3. Competitive transmission studies in ferrets for wild-type and mutant pandemic H1N1 viruses. A. Overview of PB2 amino acids
at positions 591, 627, and 701. Shown are A/California/04/09 (H1N1; Cal04) and its mutants tested in competitive transmission studies. B.–D. The
indicated pairs of viruses were mixed at a 1:1 ratio and three ferrets (one per cage) were infected intranasally with 10
6 plaque-forming units of virus
mix. One day later, one ferret each was placed in a cage adjacent to an infected ferret (‘contact’ ferret); that is, for each set of viruses, three pairs of
infected/contact ferrets were tested. Virus populations in the nasal washes of infected and contact ferrets were assessed at the indicated time points.
Grey bars; percent wild-type PB2 molecules. Colored bars; percent mutant PB2 molecules. NA, not applicable; ND, not determined (nasal wash
samples with virus titers of less than 10
2 plaque-forming units per ml were not processed for sequence analysis). Competition studies were carried
out for Cal04 (PB2-591R/627E/701D) and Cal04PB2-627K (PB2-591R/627K/701D) (B), Cal04 (PB2-591R/627E/701D) and Cal04PB2-701N (PB2-591R/
627E/701N) (C), and for Cal04 (PB2-591R/627E/701D) and Cal04-PB2-591Q (PB2-591Q/627E/701D) (D).
doi:10.1371/journal.ppat.1001034.g003
A Host-Adapting Amino Acid in Influenza Virus
PLoS Pathogens | www.plospathogens.org 6 August 2010 | Volume 6 | Issue 8 | e1001034associated with PB2-627K or PB2-591R may facilitate interaction
with a stimulatory host factor. Thus, efficient replication in
mammalian cells may require a PB2 structure that prevents the
action of the inhibitory host factor, or facilitates the action of the
stimulatory host factor. Our finding that PB2-591Q/627K (found
in human viruses) and PB2-591R/627E (found in pandemic
H1N1 viruses) adopt different conformations (i.e. a positively
charged, ‘cleft’ vs. a positively-charged residue that fills the cleft
and is located next to a negatively-charged patch) probably favors
the former possibility, since it is less likely that they would both
Figure 4. X-ray crystal structures of pandemic H1N1 and avian H5N1 PB2 proteins. Shown are the X-ray crystal structures of a pandemic
H1N1 (PB2-591R/627E) and an H5N1 PB2 protein encoding PB2-627K (PB2-591Q/627K). A. The surface of H1N1-PB2 in the region of PB2-591R and
PB2-627E (PDBID:3KHW). Color of surface is mapped by qualitative vacuum electrostatics generated by PYMOL (27). Blue=relative positive charge,
Red=relative negative charge. Residue S590, R591, and E627 are shown as stick representations underneath the surface contour and are identified
with black arrows. The side chain of R591 intrudes into the cleft shown in Fig. 4B. B. The surface of H5N1-PB2 in the region of PB2-591Q and PB2-627K
(PDBID:3KC6) shows a distinct cleft in comparison to the surface of H1N1 PB2-591R and PB2-627E (PDBID:3KHW). C. Close-up view of the interactions
of H1N1 PB2-591R with neighbouring residues. H1N1-PB2 residues A587, S590, R591, and E627 are shown in sticks model, green=carbon,
red=oxygen, blue=nitrogen. The conformation of H1N1 PB2-591R (PDBID:3KHW) is shown oriented away from PB2-627E making hydrogen bonding
and water-mediated hydrogen bonding interactions to the carbonyl oxygen of residue PB2-587A. PB2-591R fills the cleft shown in Figure 4B. Residue
S590 sits underneath E627 and blocks the conformational freedom of E627.
doi:10.1371/journal.ppat.1001034.g004
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charge introduced by either change could easily disrupt interaction
with an inhibitory host protein.
A serine at position 590 of PB2 is found in pandemic H1N1
viruses (but not consistently in older human H1N1 isolates), and
this residue (PB2-590S) has been suggested to play a role in the
enhanced replicative ability of pandemic H1N1 viruses in
mammals [13]. Our results that a basic amino acid at PB2-591
provided a replicative advantage in mammals to avian H5N1
viruses (which possess a glycine at PB2-590), argue against a
critical role of PB2-590S in the adaptation of H5N1 influenza
viruses to mammals. Our H1N1 structure shows that while the
side chain of PB2-590S is in close proximity (,4A ˚ngstroms) to
627E, the hydroxyl moiety points away from the glutamatic acid
and does not participate in hydrogen bonds or polar interactions
with the side chains of 591R or 627E. Furthermore, the side chain
atoms of PB2-590S also protrude into the positively charged cleft
and may provide a steric platform that reduces the conformational
flexibility of neighboring residue 627E. These findings suggest that
PB2-590S constrains any side chain at position 627. This
constraint may be critical for PB2-627K which may need
conformational freedom to reach its binding partner. The
constraint by PB2-590S on PB2-627E may be less critical, and
may in fact help to shield the negative charge.
Our study identifies a new marker (PB2-591R or K) for influenza
virus adaptation in mammals that compensates for the lack of PB2-
627K. This finding provides an explanation for the efficient
replication of pandemic H1N1 viruses (which possess PB2-591R) in
mammals. Our X-ray crystal structure of the C-terminal portion of a
pandemic H1N1 PB2 protein reveals changes in surface shape and
charge created by PB2-591R which may prevent an inhibitory host
factor as suggested by Mehle & Doudna [22] from binding to PB2,
hence allowing efficient influenza virus replication. Although a few
human H1N1 isolates have now been found to possess PB2-627K
(http://www.promedmail.org/pls/otn/f?p=2400:1001:19224::NO::
F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1010,
79432), this mutation did not appear to increase the severity of disease,
and does not seem to spread in human populations, consistent with
our conclusion that the PB2-627K mutation does not provide a
significant replicative advantage to pandemic H1N1 viruses. Based on
findings with H5N1 influenza viruses, it was feared that the
introduction of PB2-627K into pandemic H1N1 viruses could
increase the pathogenicity of the pandemic viruses. However, our
data and recent findings by others [13] indicate that PB2-627K does
not provide a replicative advantage in the background of a PB2
protein possessing a basic amino acid at PB2-591. From a public
health perspective, the notion that the introduction of PB2-627K into
pandemic H1N1 viruses is rare and unlikely to create a more
pathogenic variant is thus reassuring.
Materials and Methods
Viruses and cells
Human embryonic kidney (293 or 293T) cells were maintained
in Dulbecco’s modified essential medium (DMEM) containing
10% fetal calf serum and antibiotics. Madin-Darby canine kidney
(MDCK) cells were maintained in Eagle’s minimal essential
medium (MEM) containing 5% newborn calf serum. Normal
human bronchioepithelial cells (NHBE) were obtained from Lonza
(Walkersville, MD) and maintained in serum-free and hormone-
supplemented growth medium according to the manufacturer’s
instructions. All cells were incubated at 37uC with 5% CO2.
All influenza viruses used in this study were amplified in MDCK
cells. All viruses were stored at 280uC until their use in
experiments. The titers of stock viruses were determined by
plaque assays in MDCK cells (for H1N1 viruses) or NHBE cells
(for H5N1 viruses). All experiments with H5N1 viruses were
performed in enhanced biosafety level 3 (BSL3) containment
laboratories at the University of Wisconsin-Madison, which are
USDA approved for such use by the CDC and the U.S.
Department of Agriculture, or in BSL3 containment laboratories
at the University of Tokyo (Tokyo, Japan), which are approved for
such use by the Ministry of Agriculture, Forestry and Fisheries,
Japan.
Construction of plasmids and generation of wild-type
and mutant influenza viruses
The cDNAs of the A/chicken/Indonesia/UT3091/05 (H5N1;
CkUT3091), A/Indonesia/UT3006/05 (H5N1; UT3006), and A/
California/04/09 (H1N1; Cal04) viruses were synthesized by
reverse transcription as previously described [23,24]. Viruses were
amplified and titrated as described above. All viruses were
sequenced to ensure the absence of unwanted mutations.
Mutations in the PB2 genes of CkUT3091 or Cal04 viruses
were generated by PCR amplification of the respective RNA
polymerase I PB2 construct with primers possessing the desired
mutations (primer sequences will be provided upon request). All
constructs were sequenced to ensure the absence of unwanted
mutations.
Minireplicon assays
To assess the viral polymerase activity, we performed luciferase
activity-based minireplicon assay as described previously [15]
using the following plasmids; expression plasmids for Cal04-PB2, -
PB1, -PA, and -NP (0.2 mg each), pPolI-WNA-Fluc (0.02 mg),
which express NA gene encoding firefly luciferase gene, and
pGL4.74[hRluc/TK] (Promega, 0.02 mg). The luciferase activity
in the plasmid-transfected 293 cells was measured by Dual-
Luciferase Reporter Assay System (Promega) at 24 h post-
transfection.
Growth curves in NHBE or MDCK cells
NHBE cells (Lonza) were infected with the indicated viruses at a
multiplicity of infection (m.o.i) of 0.0005. One hour later, the viral
inoculum was removed and replaced with bronchial epithelial
growth medium (SAGM; Cambrex) containing bovine pituitary
extract (BPE; 30 mg/ml), hydrocortisone (0.5 mg/ml), human
epidermal growth factor (hEGF; 0.5 ng/ml), epinephrine
(0.5 mg/ml), transferrin (10 mg/ml), insulin (5 mg/ml), triiodothy-
ronine (6.5 ng/ml), bovine serum albumin – fatty-acid free (BSA-
FAF; 50 mg/ml), retinoic acid (RA; 0.1 ng/ml), gentamycin
(30 mg/ml) and amphotericin B (15 ng/ml). Infected cells were
incubated at 37uC and 5% CO2. At the indicated times post
infection, the virus titers in the cell culture supernatant were
determined by plaque assays in NHBE cells. For the determination
of viral growth kinetics in MDCK cells, cells were infected at an
m.o.i. of 0.001; at the indicated time points, virus titers were
determined by plaque assays.
Virulence in mice
Six-week-old female BALB/c mice (Japan SLC Inc., Shizuoka,
Japan; The Jackson Laboratory, Bar Harbor, Maine, USA) were
used in this study. Baseline body weights were measured prior to
infection. Four mice per group were anesthetized with isoflurane
and intranasally inoculated with 10
1–10
6 PFU (50 ml) of
CkUT3001 or CkUT3091-PB2-Q591K, or with 10
3 or 10
6 PFU
of Cal04 possessing wild-type or mutant PB2 protein. Body weight
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weight loss of more than 25% of pre-infection values were
euthanized. For virus titration in organs, mice were infected
intranasally with 10
5 PFU of virus and euthanized on days 3 and 6
postinfection.
Ferret competition-transmission study
We used six-to-seven-month-old female ferrets (Triple F Farms,
Sayre, PA), which were serologically negative by hemagglutination
inhibition (HI) assay for currently circulating human influenza
viruses (including pandemic H1N1 viruses). The animals were
housed in adjacent transmission cages that prevent direct and
indirect contact between animals but allow spread of influenza
virus through the air. Three ferrets were intranasally inoculated
with 10
6 plaque-forming units (pfu; in 500 ml) of the mixture of
Cal04 and mutant virus at a 1:1 ratio (0.5610
6 pfu of Cal04 plus
0.5610
6 pfu of mutant virus). One day after infection, three naive
ferrets were each placed in a cage adjacent to an inoculated ferret
(contact ferrets). Hence, we tested three pairs of infected/contact
ferrets for each virus. Nasal washes from ferrets were collected on
days 1, 3, 5, and 7 post-infection or co-housing and titrated for
virus titers in MDCK cells. Samples with greater than 1610
2 pfu/
ml of virus were subjected to sequence analysis as described below.
All animal experiments were carried out in accordance with
institutional guidelines.
Sequence analysis of viruses obtained from infected or
contact ferrets
Viral RNA was extracted from nasal wash samples and twice
from the inoculum (to verify the 1:1 ratio of the two test viruses).
The cDNAs were synthesized as previously described [23]. A
panel of PCR primer pairs was used to generate 410 base pair
amplicons of the PB2 region covering 591Q, 627K, and 701N of
A/California/04/2009. All primers contained Roche/454 Tita-
nium Amplicon adapter sequences and distinctive multiplier
identifier (MID) tags engineered at their 59 termini. After gel
purification and normalization to 10
8 molecules/ml, emulsion
PCR was performed on four pools containing 14 MID-tagged
amplicons each.
The resulting pools were pyrosequenced in individual regions
of a 70675 PicoTiterPlate with a 16-well gasket on a Roche/454
GS FLX instrument following protocols provided by the
manufacturer (www.454.com). An average of 2221 sequence
reads was obtained for each sample (range: 705–5102). All
sequences from a single time point were aligned to the PB2
sequence of A/California/04/09 (Roche/454 AVA software).
The frequencies of wild-type and mutant amino acids at residues
591, 627, and 701 were tabulated from the aligned sequences. To
confirm the pyrosequencing results, independent PB2 sequences
from 37 of the 42 samples were generated using alternative sets of
PCR primers and pyrosequenced using the Roche/454 FLX
chemistry.
X-ray crystal structure determination of PB2 C-terminal
domains
Codon engineered synthetic genes for the PB2 gene of influenza
A virus strains A/Vietnam/1203/04 (H5N1) (AAT73550) and A/
Mexico/InDRE4487/09 (H1N1) (ACQ73384) were designed in
Gene Composer (Emerald BioSystems, Bainbridge Island, WA)
using a combined E. coli and baculovirus codon usage table with a
threshold setting of 0.2% and synthesized (DNA 2.0, Menlo Park,
CA) [25,26]. The C-terminal amino acid residues 538–741 from
both strains were cloned into an engineered pET vector using the
Polymerase Incomplete Primer Extension (PIPE) cloning technol-
ogy [27]. Cloning, expression, and purification followed reported
protocols from the Seattle Structural Genomics Center for
Infectious Disease [28]. Constructs were expressed in vectors
containing an N-terminal 66His Smt fusion protein [29]. Site
specific removal of the 11kDA 66His Smt fusion partner was
accomplished with 0.2 mg Ulp1 protease/mg of recombinant
target [29,30]. Final protein buffer composition following size
Table 2. X-ray crystallographic data collection and
refinement statistics.
PDBID 3KHW 3KC6 3L56
Protein PB2, 538–741 PB2, 538–741 PB2, 538–759
Strain A/Mexico/
INDRE4487/
2009(H1N1)
A/Vietnam/
1203/
2004(H5N1)
A/Vietnam/
1203/
2004(H5N1)
Data Collection
space group P212121 P212121 P21
A 53.86 33.08 41.04
B 68.19 65.69 57.00
C 107.35 96.85 83.08
A9 0 9 0 9 0
B 90 90 102.4
C 90 90 90
# molecules/asymmetric unit 2 1 2
Wavelength [A ˚] 1.54178 1.54178 1.54178
Resolution [A ˚]
(1) 50.0–2.08 50.0–2.08 50–2.30
(2.12–2.08) (2.12–2.08) (2.34–2.30)
Redundancy 6.8 (4.6) 5.7 (4.4) 3.5 (2.2)
Unique 24405 (1121) 13176 (621) 16536 (678)
Completeness [%] 99.5 (93.4) 99.1 (96.6) 98.1 (82.0)
Rmerge [%]
(2) 7.4 (20.9) 7.6 (27.7) 2.9 (4.6)
I/sI
(3) 29.3 (5.6) 25.5 (5.3) 21.0 (18.5)
Mosaicity 0.6 0.4 0.8
Refinement Statistics
No. of reflections 23670 (1626) 12197 (861) 16526 (940)
No. of non-hydrogen atoms 3362 1607 3270
Resolution range [A ˚] 50–2.10 50.0–2.10 50–2.30
(2.15–2.10) (2.15–2.10) (2.36–2.30)
Rcryst
(4) 19.7 (18.5) 19.9 (21.6) 18.0 (19.8)
Rfree
(5) 23.8 (25.1) 24.6 (34.3) 23.7 (27.3)
FreeR, # of reflections 5%, 1218 (88) 5%, 631 (49) 5%, 840 (53)
average Bfactor [A ˚2] 7.8 9.8 12.9
Model Geometry
Bond length deviation [A ˚] 0.012 0.011 0.014
Bond angle deviation [u] 1.316 1.208 1.377
(1)Numbers in parenthesis represent highest resolution shell of data.
(2)Rmerge=(|SIhkl2,I.|/(SIhkl), where the average intensity ,I. is taken over all
symmetry equivalent measurements and Ihkl is the measured intensity for any
given reflection.
(3)I/sI is the mean reflection intensity divided by the estimated error.
(4)Rcryst=IFo|2|FcI/|Fo|, where Fo and Fc are the observed and calculated
structure factor amplitudes, respectively.
(5)Rfree is equivalent to Rcryst but calculated for 5% of the reflections chosen at
random and omitted from the refinement process.
doi:10.1371/journal.ppat.1001034.t002
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away, NJ) was 25 mM Hepes/NaOH pH 7.2, 500 mM NaCl,
2 mM DTT, 5% glycerol. Protein crystallization trials were
conducted by sitting drop vapor diffusion at 16uC in 96-well
crystallization plates. Crystallization conditions for H5N1-
PB2(538–741) were 5% octyl b-D-1-thioglucopyranoside (SBOG),
100 mM N-cyclohexyl-3-aminopropanesulfonic acid (CAPS)
pH 10.5, 1.2 M sodium phosphate, 0.2 M lithium phosphate,
0.8 M potassium phosphate at protein concentration of 8 mg/ml.
Crystallization conditions for H1N1-PB2(538–741) were 20% w/v
PEG 3350, 200 mM ammonium citrate at protein concentration
of 24 mg/ml. All crystal drop sizes used were 0.4 ml crystallant
plus 0.4 ml protein. Crystals were harvested by transfer into drops
containing crystallant plus either 25% glycerol or ethylene diol as
cryoprotectant and flash frozen in liquid nitrogen. X-ray data were
collected on a Rigaku (Rigaku Americas, The Woodlands, Texas)
FR-E+ X-ray generator equipped with a Saturn-944 CCD
detector. One degree images were collected for 30 seconds and
scaled with HKL2000 [31]. Structures were determined by
molecular replacement with the coordinates from PDBID 3CW4
using CCP4/PHASER [32]. Iterative refinement and modeling of
coordinates was conducted using REFMAC [33] and COOT
[34]. Final crystallographic refinement statistics are presented in
Table 2. Structure figures were generated using PYMOL [35].
Ethics
Our experiments in mice, ostriches, and ferrets followed the
University of Tokyo’s Regulations for Animal Care and Use and
the University of Wisconsin-Madison’s Animal Care and Use
Protocol. They were approved by the Animal Experiment
Committee of the Institute of Medical Science, the University of
Tokyo (approval number: 19–29) and the Animal Care and Use
Committee of the University of Wisconsin-Madison (protocol
number V00806), which acknowledged and accepted both the
legal and ethical responsibility for the animals, as specified in the
Fundamental Guidelines for Proper Conduct of Animal Experi-
ment and Related Activities in Academic Research Institutions
under the jurisdiction of the Ministry of Education, Culture,
Sports, Science and Technology, 2006 (Japan) and in the Animal
Welfare Act and associated Animal Welfare Regulations and
Public Health Service Policy (USA).
Supporting Information
Figure S1 Alignment of PB2 protein sequences of influenza A
viruses isolated from ostriches, emus, and rheas. Shown is the
region covering amino acid positions 591, 627, and 701.
Found at: doi:10.1371/journal.ppat.1001034.s001 (0.44 MB
TIF)
Figure S2 Polymerase activity of Cal04 PB2 variants in vitro. 293
cells were transfected with plasmids for the expression of a virus-
like RNA encoding luciferase, and with plasmids encoding the
Cal04 PB1, PA, NP, and wild-type or mutant PB2 proteins. Forty-
eight hours later, luciferase activity was assessed.
Found at: doi:10.1371/journal.ppat.1001034.s002 (0.10 MB TIF)
Figure S3 Growth curves of wild-type and mutant Cal04 viruses
in MDCK cells. Cells were infected with wild-type or mutant
Cal04 viruses at an m.o.i. of 0.001. At the indicated times post-
infection, the virus titers in the cell culture supernatant were
assessed by plaque assays. Experiments were carried out in
triplicate.
Found at: doi:10.1371/journal.ppat.1001034.s003 (0.10 MB TIF)
Figure S4 Virulence of wild-type and mutant Cal04 viruses in
mice. BALB/c mice were infected with 10
5 PFU (A)o r1 0
4 PFU
(B) of the indicated viruses and assessed daily for weight losses. For
mice infected with the PB2-627K or PB2-701N variants, one
mouse each had to be euthanized on day 5 or 6, respectively, due
to body weight loss of more than 25% of the respective pre-
infection body weight.
Found at: doi:10.1371/journal.ppat.1001034.s004 (0.17 MB
TIF)
Table S1 Biological features of PB2 variants in mice
Found at: doi:10.1371/journal.ppat.1001034.s005 (0.03 MB
DOC)
Table S2 Competitive transmission studies in ferrets for wild-
type and mutant pandemic H1N1 viruses
Found at: doi:10.1371/journal.ppat.1001034.s006 (0.04 MB XLS)
Acknowledgments
We thank M. McGregor, R. Moritz, A. Hanson, S. Basnet, C. Doyle, L.
Burley, and R. Nelson for technical assistance. We also wish to thank Chris
Wright and Evette Vlach at the University of Illinois at Urbana-
Champaign High-Throughput Sequencing Center and Steve Wolinsky,
Kevin Kuntsman, Kristin Mars and Jennifer Kuntsman at Northwestern
University for outstanding support with the Roche/454 pyrosequencing
studies. Special thanks to Don Lorimer, Taryn Haffner, Michelle Dietrich,
and Becky Poplawski at Emerald BioStructures for their support in
molecular biology, protein crystallization and X-ray data collection.
Author Contributions
Conceived and designed the experiments: M. Hatta, B. Staker, S.
Watanabe, T. Watanabe, P. Myler, I. Phan, A. Raymond, E. Smith, R.
Stacy, S. Lank, R. Wiseman, B. Bimber, D. O’Connor, L. Stewart, Y.
Kawaoka. Performed the experiments: S. Yamada, M. Hatta, B. Staker,
M. Imai, K. Shinya, Y. Sakai-Tagawa, M. Ito, M. Ozawa, T. Watanabe,
S. Sakabe, C. Li, J. Kim, P. Myler, I. Phan, A. Raymond, E. Smith, R.
Stacy, S. Lank, R. Wiseman, B. Bimber, D. O’Connor, L. Stewart.
Analyzed the data: B. Staker, P. Myler, I. Phan, A. Raymond, E. Smith, R.
Stacy, S. Lank, R. Wiseman, B. Bimber, D. O’Connor, L. Stewart, Y.
Kawaoka. Contributed reagents/materials/analysis tools: C. Nidom.
Wrote the paper: G. Neumann, Y. Kawaoka.
References
1. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of
swine-origin H1N1 influenza virus. Nature 459: 931–939.
2. Yen HL, Aldridge JR, Boon AC, Ilyushina NA, Salomon R, et al. (2009)
Changes in H5N1 influenza virus hemagglutinin receptor binding domain affect
systemic spread. Proc Natl Acad Sci U S A 106: 286–291.
3. Hatta M, Gao P, Halfmann P, Kawaoka Y (2001) Molecular basis for high
virulence of Hong Kong H5N1 influenza A viruses. Science 293: 1840–1842.
4. Subbarao EK, London W, Murphy BR (1993) A single amino acid in the PB2
gene of influenza A virus is a determinant of host range. J Virol 67: 1761–
1764.
5. Li Z, Chen H, Jiao P, Deng G, Tian G, et al. (2005) Molecular basis of
replication of duck H5N1 influenza viruses in a mammalian mouse model.
J Virol 79: 12058–12064.
6. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA,
et al. (2004) Avian influenza A virus (H7N7) associated with human
conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl
Acad Sci U S A 101: 1356–1361.
7. Le QM, Sakai-Tagawa Y, Ozawa M, Ito M, Kawaoka Y (2009) Selection of
H5N1 influenza virus PB2 during replication in humans. J Virol 83:
5278–5281.
8. Van Hoeven N, Pappas C, Belser JA, Maines TR, Zeng H, et al. (2009) Human
HA and polymerase subunit PB2 proteins confer transmission of an avian
influenza virus through the air. Proc Natl Acad Sci U S A 106: 3366–3371.
9. Steel J, Lowen AC, Mubareka S, Palese P (2009) Transmission of influenza virus
in a mammalian host is increased by PB2 amino acids 627K or 627E/701N.
PLoS Pathog 5: e1000252.
A Host-Adapting Amino Acid in Influenza Virus
PLoS Pathogens | www.plospathogens.org 10 August 2010 | Volume 6 | Issue 8 | e100103410. Shinya K, Makino A, Ozawa M, Kim JH, Sakai-Tagawa Y, et al. (2009) Ostrich
involvement in the selection of H5N1 influenza virus possessing mammalian-
type amino acids in the PB2 protein. J Virol 83: 13015–13018.
11. Kuzuhara T, Kise D, Yoshida H, Horita T, Murazaki Y, et al. (2009) Structural
basis of the influenza A virus RNA polymerase PB2 RNA-binding domain
containing the pathogenicity-determinant lysine 627 residue. J Biol Chem 284:
6855–6860.
12. Tarendeau F, Crepin T, Guilligay D, Ruigrok RW, Cusack S, et al. (2008) Host
determinant residue lysine 627 lies on the surface of a discrete, folded domain of
influenza virus polymerase PB2 subunit. PLoS Pathog 4: e1000136.
13. Mehle A, Doudna JA (2009) Adaptive strategies of the influenza virus
polymerase for replication in humans. Proc Natl Acad Sci U S A.
14. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in
vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:
1021–1025.
15. Ozawa M, Fujii K, Muramoto Y, Yamada S, Yamayoshi S, et al. (2007)
Contributions of two nuclear localization signals of influenza A virus
nucleoprotein to viral replication. J Virol 81: 30–41.
16. Herfst S, Chutinimitkul S, Ye J, de Wit E, Munster VJ, et al. (2010) Introduction
of virulence markers in PB2 of pandemic swine-origin influenza virus does not
result in enhanced virulence or transmission. J Virol 84: 3752–3758.
17. Zhu H, Wang J, Wang P, Song W, Zheng Z, et al. (2010) Substitution of lysine at
627 position in PB2 protein does not change virulence of the 2009 pandemic
H1N1 virus in mice. Virology 401: 1–5.
18. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, et al. (2009)
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses
in ferrets and mice. Science 325: 484–487.
19. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, et al. (2009)
Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in
ferrets. Science 325: 481–483.
20. Brown EG, Bailly JE (1999) Genetic analysis of mouse-adapted influenza A virus
identifies roles for the NA, PB1, and PB2 genes in virulence. Virus Res 61:
63–76.
21. Yao Y, Mingay LJ, McCauley JW, Barclay WS (2001) Sequences in influenza A
virus PB2 protein that determine productive infection for an avian influenza
virus in mouse and human cell lines. J Virol 75: 5410–5415.
22. Mehle A, Doudna JA (2008) An inhibitory activity in human cells restricts the
function of an avian-like influenza virus polymerase. Cell Host Microbe 4:
111–122.
23. Katz JM, Wang M, Webster RG (1990) Direct sequencing of the HA gene of
influenza (H3N2) virus in original clinical samples reveals sequence identity with
mammalian cell-grown virus. J Virol 64: 1808–1811.
24. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, et al. (1999) Generation
of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A
96: 9345–9350.
25. Lorimer D, Raymond A, Walchli J, Mixon M, Wallace E, et al. (2009) Gene
Composer: Database software for protein construct design, codon engineering,
and gene synthesis. BMC Biotechnol 9: 36.
26. Raymond A, Lovell S, Lorimer D, Walchli J, Mixon M, et al. (2009) Combined
protein construct and synthetic gene engineering for heterologous protein
expression and crystallization using Gene Composer. BMC Biotechnol 9: 37.
27. Klock HE, Koesma EJ, Knuth MW, Lesley SA (2008) Combining the
polymerase incomplete primer extension method for cloning and mutagenesis
with microscreening to accelerate structural genomics efforts. Proteins 1:
982–994.
28. Myler PJ, Stacy R, Stewart L, Staker B, Van Voorhis WC, et al. (2009) The
Seattle Structural Genomics Center for Infectious Disease (SSGCID). Infect
Disord Drug Targets.
29. Mossessova E, Lima CD (2000) Ulp1-SUMO crystal structure and genetic
analysis reveal conserved interactions and a regulatory element essential for cell
growth in yeast. Mol Cell 5: 865–876.
30. Li SJ, Hochstrasser M (1999) A new protease required for cell-cycle progression
in yeast. Nature 398: 246–251.
31. Otwinowski Z, Minor W (1997) Processing of X-ray Diffraction Data Collected
in Oscillation Mode Methonds in Enzymology 276: 307–326.
32. Collaborative Computational Project N (1994) The CCP4 Suite: Programs for
Protein Crystallography. Acta Cryst D D50: 760–763.
33. Murshudova GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular
structures by the maximum-likelihood method. Acta Crystallographica Section
D-Biological Crystallography D53: 240–255.
34. Emsley P, Cowtan K (2004) Coot: model- building tools for molecular graphics.
Acta Crystallographica Section D-Biological Crystallography 60: 2126–2132.
35. DeLano WL, ed. (2002) The PyMOL User’s Manual: DeLano Scientific, Palo
Alto, CA, USA.
A Host-Adapting Amino Acid in Influenza Virus
PLoS Pathogens | www.plospathogens.org 11 August 2010 | Volume 6 | Issue 8 | e1001034